Endpreeclampsia.org’s Post

Thank you, Comanche Biopharma, for all the risk you’ve taken to invest in maternal healthcare when others wouldn’t, to find solutions and modernize how we treat preeclampsia. Thank you for recognizing this vast unmet need and taking action.  We are proud to partner with you in moving medicine forward based on science so that someday we can give moms, babies and families better options, and reduce maternal and fetal illness and death due to hypertensive disorders of pregnancy. #Endpreeclampsia #preeclampsia #eclampsia #gestationalhypertension

View organization page for Comanche Biopharma, graphic

3,460 followers

Today, as part of our ongoing Preeclampsia Champions of Change series and in honor of #WorldPreeclampsiaDay we feature a Q&A with Kara Boeldt, Founder and Director of Endpreeclampsia.org, a group who seeks to make an impact in education, advocacy, and support. We’re also honored to have Kara serve as a member of Comanche’s Patient Advisory Board. Kara experienced liver failure, kidney failure, and cerebral edema due to severe #preeclampsia at 31 weeks gestation, resulting in the emergent delivery of her daughter. She ultimately transformed this traumatic personal experience with preeclampsia into an opportunity to help others. Kara decided to build a supportive community to help people navigate through this time of often heightened uncertainty and anxiety, giving them a safe place to share their concerns, frustrations, and grief, and to ask questions of trained peer-educators. Today, this community has over 50,000 members in 115 countries. Read more about Kara’s inspiring story: https://bit.ly/3UUX6xY Photo: Kara with her daughter, born at 31 weeks and weighing just 2.5 pounds. #maternalhealth #patientadvocacy #advocacy #pregnancy

  • No alternative text description for this image

Thank you, EndPreeclampsia.org, for the important work you do on behalf of women and their families around the world! We're honored to join you in shining a light on the serious unmet needs surrounding preeclampsia, as we advance our mission to develop and make globally available the first therapy targeting a root cause of preeclampsia.

To view or add a comment, sign in

Explore topics